Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2017—Hamilton Storage introduced its SAM HD, a low-capacity automated sample management system that aims to be a reliable, walkaway solution for labs seeking to transition from manual to automated sample storage.
February 2017—Genospace launched the Genospace Trial Match, a mobile application that enables real-time clinical trial matching at the point of care based on molecular profiling and clinical data. The app allows leaders in precision medicine to streamline the clinical trial matching process by identifying patients who may qualify for open and enrolling clinical trials.
February 2017—Micromedic Technologies introduced CellDetect, a staining assay for the early detection of bladder cancer in urine specimens, to the U.S. market. The assay uses color and morphology to differentiate between normal and malignant cells.
February 2017—Visiopharm A/S, headquartered in Hørsholm, Denmark, announced its acquisition of LRI Imaging AB, based in Sweden.
February 2017—Myriad Genetics announced that its BRACAnalysis CDx test accurately identified patients who may benefit from treatment with olaparib. The test was included in the SOLO2 study as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca.
February 2017—Horizon Discovery Group has entered into an original equipment manufacturer agreement with CareDx. Under the terms of the new agreement, Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for monitoring transplanted organ rejection.
February 2017—Quidel has received 510(k) clearance from the Food and Drug Administration to market its Solana Strep Complete Assay for the rapid and qualitative detection and differentiation of Streptococcus pyogenes (group A beta-hemolytic streptococcus) and Streptococcus dysgalactiae (pyogenic group C and G beta-hemolytic streptococcus) nucleic acids isolated from throat swab specimens obtained from symptomatic patients.
February 2017—Nanomix released a rapid diagnostic test panel designed to quickly evaluate patients affected by sepsis and that runs on Nanomix eLab, the company’s handheld diagnostic system. Designed for emergency medical and other point-of-care needs, the test uses a single patient blood, plasma, or serum sample to provide actionable results within 10 minutes.
February 2017—Streck’s Sperm-Chex and Sperm-Chex Post VC, both with stabilized sperm cells, are now assayed for the Makler Counting Chamber. Sperm-Chex has two clinically significant levels of control to simulate the sperm cell concentration that technologists encounter in patient samples. It has the same chamber loading and optical characteristics as a patient sample. Sperm-Chex verifies the sperm analysis process and tests the technologist’s proficiency in sperm cell quantification and qualification.
February 2017—Centogene, a genetics company focused on the early diagnosis of rare hereditary disorders, has introduced the Illumina HiSeq X whole genome sequencing platform …
